Clinical trials · New York, NY
Alzheimer’s disease clinical trials in New York
We’re tracking 56 recruiting alzheimer’s disease studies with a site in or near New York — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07758660Enrolling by invitationPhase 2
Brain scan study for Alzheimer's research
This study uses brain scans (PET) to look at changes in the brain that may be related to memory problems or Alzheimer's disease. It aims to improve understanding of the disease and may help develop better treatments.
New York, New YorkAges 50 years+ - NCT07284472RecruitingPhase 2/Phase 3
Testing drugs for agitation in Alzheimer's disease
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
New York, New YorkAges 55–90 - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
New York, New YorkAges 60 years+ - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
New York, New YorkAges 55–90 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
New York, New YorkAges 18 years+ - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Brooklyn, New YorkAges 55–90 - NCT05597124RecruitingPhase 2
Exercise program to improve brain health in older Black adults
This Phase 2 study tests whether a structured exercise program can improve brain health in adults age 60 and older who are less active and have early thinking/memory concerns. It may help maintain or improve thinking abilities over time, with medical supervision throughout the study.
Newark, New JerseyAges 60 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Newark, New JerseyAges 40–85 - NCT06995638Recruiting
Multitasking training for older adults
This study tests whether a special online training program can help older adults improve their ability to multitask and stay focused. You'll do some computer exercises at home and come in for a few checkups, including a blood test.
Newark, New JerseyAges 60–75 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Queens, New YorkAges 50–85 - NCT06810960Recruiting
Leqembi use in South Korean Alzheimer's patients
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
Nutley, New JerseyAges 19 years+ - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Inwood, New YorkAges 55–90 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
The Bronx, New YorkAges 55–95 - NCT05295615Recruiting
Pulsed magnetic treatment for mild to moderate Alzheimer’s
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
Hackensack, New JerseyAges 50–100 - NCT04165109Recruiting
Down syndrome study to test memory and thinking changes
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Staten Island, New YorkAges 25–55 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Staten Island, New YorkAges 55–90 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Staten Island, New YorkAges 55–90 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Staten Island, New YorkAges 50–85 - NCT07012993RecruitingPhase 2
Very low dose PET brain scan study
This study tests whether using a very low dose of radiation for a brain PET scan can still give clear images. If you are eligible, you will get a type of radioactive tracer that helps show amyloid plaques in the brain, often used in Alzheimer's research.
Englewood, New JerseyAges 18–120 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Lake Success, New YorkAges 60–85 - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Springfield, New JerseyAges 50–90 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Springfield, New JerseyAges 50–92 - NCT07602582RecruitingPhase 3
Donanemab Extension Study for Alzheimer's Disease
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
Springfield, New JerseyAges 55 years+ - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Woodmere, New YorkAges 55–90
Hear when a new Alzheimer’s disease trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Alzheimer’s disease trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Mid Hudson Medical Research · 5 studies
- The Cognitive and Research Center of New Jersey · 5 studies
- Local Institution · 4 studies
- Advanced Memory Research Institute of New Jersey · 2 studies
- Columbia University Irving Medical Center · 2 studies
- Five Towns Neurology · 2 studies
- Integrative Clinical Trials · 2 studies
- Advanced Clinical Institute
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alzheimer’s disease studies in New York.
Common questions
- Are there alzheimer’s disease clinical trials near New York?
- Yes. We're currently tracking 56 recruiting alzheimer’s disease studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.